Solving spondyloarthropathy

Putting big mouths and big ideas behind microphones The Physio Matters Podcast offers free education to healthcare professionals, particularly physiotherapists.  The Physio Matters Podcast session 26 was funded by NASS and features physiotherapist Jack March interviewing Dr Karl Gaffney...


New NICE AS guidance on anti TNF therapy published

New NICE guidance on anti TNF therapy for ankylosing spondylitis and non-radiographic axial spondyloarthritis has been published. We are delighted to report the guidances contain everything NASS campaigned for. We have summarised the recommendations below but you can read...


Members' Day 2016

We are delighted to announce we are taking bookings for NASS Members' Day 2016, which will be held at Bath Spa University on Saturday 4 June 2016. To coincide with NASS' 40th birthday celebrations we are returning to the...


New drug accepted for use in NHS Scotland

The Scottish Medicines Consortium (SMC) have announced that golimumab (Simponi®) is accepted for use within NHS Scotland for the treatment of adults with severe, active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated CRP and/or MRI...


Research Fund returns for 2016

NASS is delighted to announce the return of our Research Fund and Educational Bursary Fund.  As many of you will know back in 2013 we held an event at Lancaster University and then asked our supporters to tell us...


Ladies' golf club raises 1,440 for NASS

The Ladies Team at the St Pierre Golf Club & Country Club in Chepstow recently presented NASS with a cheque for a fantastic £1,440. The team selects a different charity partner every January to benefit from a series of...


Biosimilar version of etanercept approved in Europe

A version of the anti TNF therapy etanercept has been granted marketing authorisation in the EU for the treatment of rheumatic conditions including axial spondyloarthritis (both non radiographic axial spondyloarthritis and ankylosing spondylitis). Developed by Samsung Bioepis, the new drug,...


Newly diagnosed? Come to an AS & You!

We're 7 events into our AS & You schedule! So far they have been excellent events - everyone has learned so much about their condition or their partner's condition.  The events are specially designed for people who have been diagnosed...


DBC gain media coverage for ESA cuts

Following on from our Parliamentary lobby a few weeks ago, this weekend the Disability Benefits Consortium (DBC) gained brilliant coverage of the proposed cuts to Employment and Support Allowance (ESA) which would leave those in the Work Related Activity...


NICE working on guidance for secukinumab

The Department of Health has asked the National Institute for Health and Care Excellence (NICE) to conduct an appraisal secukinumab for treating AS. Secukinumab is NOT an anti TNF. It is a human monoclonal antibody that selectively neutralises circulating...